Company intelligence / Profile preview
ASDERA
New York, New York, United Statesasdera.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Preclinical
01
Overview
ASDERA has a Phase 3-ready drug (mefenamic acid derivative) for preventing mutism in autism. They also have programs for Alzheimer's, Parkinson's, breast cancer, and other conditions at various stages of development.
- Therapeutic areas
- OncologyPsychiatryGastroenterologyCardiovascularNeurology
- Modalities
- Small molecule drugsOligonucleotideChemical drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on ASDERA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASDERA.